Avalon Advisors LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.3% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 284,681 shares of the company’s stock after purchasing an additional 3,720 shares during the period. Johnson & Johnson accounts for about 1.1% of Avalon Advisors LLC’s investment portfolio, making the stock its 18th biggest holding. Avalon Advisors LLC’s holdings in Johnson & Johnson were worth $36,481,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. TT International grew its holdings in Johnson & Johnson by 254.1% during the first quarter. TT International now owns 136,518 shares of the company’s stock valued at $15,930,000 after purchasing an additional 97,969 shares during the period. Eagle Global Advisors LLC boosted its stake in shares of Johnson & Johnson by 1.6% in the first quarter. Eagle Global Advisors LLC now owns 77,460 shares of the company’s stock worth $9,927,000 after acquiring an additional 1,221 shares during the period. Great West Life Assurance Co. Can boosted its stake in shares of Johnson & Johnson by 1.9% in the first quarter. Great West Life Assurance Co. Can now owns 3,784,116 shares of the company’s stock worth $485,495,000 after acquiring an additional 72,159 shares during the period. Trexquant Investment LP boosted its stake in shares of Johnson & Johnson by 28.2% in the first quarter. Trexquant Investment LP now owns 22,542 shares of the company’s stock worth $2,889,000 after acquiring an additional 4,959 shares during the period. Finally, NuWave Investment Management LLC bought a new position in shares of Johnson & Johnson in the fourth quarter worth about $680,000. 66.80% of the stock is owned by institutional investors and hedge funds.

In other Johnson & Johnson news, COO Michael E. Sneed sold 29,000 shares of the company’s stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the sale, the chief operating officer now directly owns 59,124 shares in the company, valued at $7,969,915.20. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of the company’s stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $137.18, for a total value of $1,083,584.82. Following the sale, the chief accounting officer now owns 25,725 shares in the company, valued at $3,528,955.50. The disclosure for this sale can be found here. 0.22% of the stock is currently owned by corporate insiders.

Shares of Johnson & Johnson stock opened at $139.49 on Friday. Johnson & Johnson has a 12 month low of $118.62 and a 12 month high of $148.32. The company has a market cap of $373.89 billion, a P/E ratio of 19.11, a PEG ratio of 2.13 and a beta of 0.69. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.65 and a quick ratio of 1.33.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 17th. The company reported $2.10 EPS for the quarter, beating analysts’ consensus estimates of $2.06 by $0.04. Johnson & Johnson had a return on equity of 32.79% and a net margin of 1.70%. The company had revenue of $20.83 billion during the quarter, compared to analyst estimates of $20.39 billion. During the same period in the prior year, the company earned $1.83 earnings per share. The firm’s revenue was up 10.6% on a year-over-year basis. research analysts predict that Johnson & Johnson will post 8.14 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 11th. Investors of record on Tuesday, August 28th were paid a dividend of $0.90 per share. This represents a $3.60 dividend on an annualized basis and a yield of 2.58%. The ex-dividend date was Monday, August 27th. Johnson & Johnson’s payout ratio is presently 49.32%.

A number of equities analysts have recently weighed in on JNJ shares. Credit Suisse Group set a $151.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, June 12th. Jefferies Financial Group set a $145.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research note on Sunday, July 15th. ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Sanford C. Bernstein started coverage on Johnson & Johnson in a research note on Wednesday, June 27th. They issued a “market perform” rating and a $129.00 price objective for the company. Finally, Goldman Sachs Group raised Johnson & Johnson from a “sell” rating to a “neutral” rating in a research note on Thursday, July 12th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the company. Johnson & Johnson has a consensus rating of “Hold” and an average price target of $142.87.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Trading Strategy Methods for Individual Investors

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.